HIF1A and neoplasm: Such effects have been attracting attention, and iron chelating drugs are being explored as potential therapeutic drugs for cancer therapy.[31, 32] Because they upregulate the expression of HIF1‐α and have a short circulating half‐life, they have tumor suppressing effects by inducing iron depletion.